- severe obesity (bmi>40) - uncontrolled type ii diabetes (hba1c >8.0) - uncontrolled systolic hypertension (>160mmdehg) - acute pancreatitis - chronic diarrhea or constipation - inflammatory bowel disease - blood clotting disease - immunosuppression derived from cancer, post-transplantation, auto-immune disease or hiv - severe and active seasonal allergies - pregnancy or lactation - glucose 6p-dehydrogenase deficiency - regular use of probiotic or antibiotic within 2 weeks before entering the trial - severe or uncontrolled chronic respiratory diseases (asthma, copd or cystic fibrosis)

- severe obesity (bmi>40) - uncontrolled type ii diabetes (hba1c >8.0) - uncontrolled systolic hypertension (>160mmdehg) - acute pancreatitis - chronic diarrhea or constipation - inflammatory bowel disease - blood clotting disease - immunosuppression derived from cancer, post-transplantation, auto-immune disease or hiv - severe and active seasonal allergies - pregnancy or lactation - glucose 6p-dehydrogenase deficiency - regular use of probiotic or antibiotic within 2 weeks before entering the trial - severe or uncontrolled chronic respiratory diseases (asthma, copd or cystic fibrosis)